Discovery of Novel Small-Molecule FAK Activators Promoting Mucosal Healing.

Gastrointestinal mucosal wounds are common to patients injured by factors as diverse as drugs, inflammatory bowel disease, peptic ulcers, and necrotizing enterocolitis. However, although many drugs are used to ameliorate injurious factors, there is no drug available to actually stimulate mucosal wound healing. Focal adhesion kinase (FAK), a nonreceptor tyrosine kinase, induces epithelial sheet migration and wound healing, making FAK a potential pharmacological target in this regard. In our previous research, we found a lead compound with drug-like properties, ZINC40099027, which promotes FAK phosphorylation, inducing mucosal healing in murine models. Herein we describe the design and optimization of a small library of novel FAK activators based on ZINC40099027 and their applications toward human intestinal epithelial wound closure and mouse ulcer healing.
Competing Interests: The authors declare the following competing financial interest(s): M.D.B. and V.J.G. are co-inventors on a patent application filed by the University of North Dakota and the University of Minnesota describing the use of FAK-activating small molecules to promote mucosal healing.
(© 2021 American Chemical Society.)